{{Rsnum
|rsid=854548
|Gene=PPP1R9A
|Chromosome=7
|position=95296508
|Orientation=plus
|GMAF=0.2971
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PPP1R9A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 4.4 | 46.9 | 48.7
| HCB | 5.2 | 37.0 | 57.8
| JPT | 7.1 | 41.6 | 51.3
| YRI | 19.9 | 47.9 | 32.2
| ASW | 26.3 | 35.1 | 38.6
| CHB | 5.2 | 37.0 | 57.8
| CHD | 4.7 | 35.5 | 59.8
| GIH | 5.0 | 33.0 | 62.0
| LWK | 13.9 | 52.8 | 33.3
| MEX | 15.5 | 29.3 | 55.2
| MKK | 14.2 | 40.6 | 45.2
| TSI | 5.1 | 27.3 | 67.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs854548
|Name_s=
|Gene_s=PPP1R9A, PON1
|Feature=
|Evidence=PubMed ID:18615156
|Annotation=This variant is significantly associated with the efficacy of anti-TNF treatment in rheumatoid arthritis (Adjusted P-value: 0.000003; OR: 8.5 (2.6, 36.5)). The study is a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively followed after beginning of anti-TNF therapy.
|Drugs=adalimumab; etanercept; infliximab
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162928824
}}

{{PMID Auto
|PMID=20423481
|Title=Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs854548
|overall_frequency_n=96
|overall_frequency_d=128
|overall_frequency=0.75
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=85
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22884547
|Title=Association analysis of PON polymorphisms in sporadic ALS in a Chinese population.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}